Janney Capital Management’s Darling Ingredients DAR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$270K Sell
7,505
-249
-3% -$8.43K 0.02% 231
2025
Q3
$239K Sell
7,754
-204
-3% -$6.81K 0.01% 226
2025
Q2
$302K Sell
7,958
-678
-8% -$22.3K 0.02% 200
2025
Q1
$270K Buy
8,636
+5
+0.1% +$175 0.02% 202
2024
Q4
$291K Buy
8,631
+1,899
+28% +$71.8K 0.02% 210
2024
Q3
$250K Sell
6,732
-271
-4% -$10.2K 0.02% 224
2024
Q2
$257K Sell
7,003
-60
-0.8% -$2.49K 0.02% 207
2024
Q1
$328K Buy
+7,063
New +$311K 0.02% 202
2023
Q4
Sell
-4,387
Closed -$229K 238
2023
Q3
$229K Buy
4,387
+119
+3% +$7.43K 0.02% 201
2023
Q2
$272K Buy
4,268
+124
+3% +$7.56K 0.02% 209
2023
Q1
$242K Buy
4,144
+488
+13% +$30.7K 0.02% 208
2022
Q4
$229K Sell
3,656
-651
-15% -$45.9K 0.02% 226
2022
Q3
$285K Buy
+4,307
New +$300K 0.02% 179

Other funds holding DAR

Janney Capital Management's DAR Position: Q4 2025 in Review

Janney Capital Management reduced its Darling Ingredients (DAR) stake by 3.2% in Q4 2025, selling an estimated $8.43K and leaving 7,505 shares worth $270K. The position accounts for 0.02% of the portfolio, ranked #231.

Janney Capital Management first reported a position in DAR in Q3 2022 and has held it in 13 quarters since. The position peaked at $328K in Q1 2024. 480 funds tracked by Wall St. Rank hold DAR as of Q4 2025.

  • Janney Capital Management held 7,505 shares of Darling Ingredients worth $270K as of Q4 2025.
  • Janney Capital Management sold 249 Darling Ingredients shares in Q4 2025, an estimated $8.43K.
  • Darling Ingredients made up 0.02% of Janney Capital Management's portfolio in Q4 2025, its #231 holding.
  • Janney Capital Management first reported a position in Darling Ingredients in Q3 2022 and has held it in 13 quarters since.
  • Janney Capital Management's Darling Ingredients position peaked at $328K in Q1 2024.
  • 480 funds tracked by Wall St. Rank held Darling Ingredients as of Q4 2025.

Based on Janney Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.